Lin C.-.JIA-HORNG KAO2021-09-042021-09-0420071058-4838https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249892208&doi=10.1086%2f518386&partnerID=40&md5=96b92691335c553f23165cd07037f332https://scholars.lib.ntu.edu.tw/handle/123456789/582161[SDGs]SDG3hepatitis B(e) antigen; interferon; peginterferon; ribavirin; Chinese; chronic hepatitis; cost effectiveness analysis; drug efficacy; drug megadose; genotype; hepatitis B; Hepatitis B virus; human; letter; low drug dose; nonhuman; priority journal; Taiwan; treatment duration; treatment response; virus carrier; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon Alfa-2a; Male; Polyethylene Glycols; Prognosis; Treatment OutcomeTo genotype or not to genotype: Toward an optimal tailoring of treatment of chronic hepatitis B [3]letter10.1086/518386175164162-s2.0-34249892208